Table 3 Articles used for Aβ OR analyses in the Cognitively Unimpaired (CU) group
Study | Centre/cohort | Subjects (n) | Age (mean (SD), or median (range)) | Measurement technique (cut-offs) | Follow-up (months) | Conversion to | |
|---|---|---|---|---|---|---|---|
Mean (SD) | Median (range) | ||||||
ADNI | ADNI | 578 | 72.9 (6.3) | amyloidPET (SUVR >1.11), CSF Aβ42 (<977 pg/mL) | 69 (48) | 54 | MCI or unspecified dementia |
Arruda, 2023 [33] | Florida Alzheimer’s Disease Research Center | 70 | 70.2 (6.5) | amyloidPET (v.r.) | 22.9 (7.1) | n.d. | MCI or unspecified dementia |
Baldeiras, 2022 [34] | Coimbra University Hospital; Hospital de Braga; Unidade Local de Saude de Matosinhos; Centro Hospi- ´ talar Baixo Vouga; Hospital Egas Moniz; Hospital de Faro, Portugal | 24 | 63.6 (8.9) | CSF Aβ42/40 ratio (<0.068) | n.d. | n.d. (12-50) | MCI or unspecified dementia |
Dang, 2018 [53] | AIBL (The Australian Imaging, Biomarker & Lifestyle Flagship Study of Ageing) | 599 | 70 (60 - 80) | amyloidPET (SUVR >1.40) | 66.9 | 88.5 | MCI or unspecified dementia |
Ebenau, 2020 [54] | ADC (Amsterdam Dementia Cohort, SCIENCe! Subjective Cognitive Impairment Cohort) | 342 | 60.0 (9.0) | amyloidPET (v.r.), CSF Aβ42 (<<813 pg/mL) | 36 ( 24) | n.d. | MCI or unspecified dementia |
Grontvedt, 2020 [14] | Department of Neurology, Univ. Hosp. Trondheim, Norway | 55 | 68 (53 - 79) | CSF Aβ42 | n.d. | 108 (72 - 120) | unspecified dementia |
Hanseeuw, 2021 [41] | Neurology Department, Saint-Luc University Hospital, Belgium | 50 | 71.4 ( 7.5) | amyloidPET (v.r.) | 38.4 (15.6) | n.d. | unspecified dementia |
Hatashita, 2019 [55] | Department of Neurology, Shonan-Atsugi Hospital, Atsugi, Japan | 32 | 71.0 (5.9) | PET (SUVR >1.39) | 72 (21.6) | n.d. | MCI or unspecified dementia |
Lopez, 2018 [44] | Ginkgo biloba memory study (GEM [Ginkgo Evaluation of Memory] Study, USA | 148 | 84.2 (2.5) | amyloidPET (SUVR >1.57) | 68.4 (20.4) | n.d. | MCI or unspecified dementia |
Ossenkoppele, 2022 [56] | BioFINDER-1, -2 | 258 | 68.8 (10.1) | amyloidPET (SUVR >1.03 in BioFINDER-1, -2) | 41.8 (18.9) | n.d. | unspecified dementia |
Roberts, 2018 [50] | MCSA (Mayo Clinic Study of Aging) | 1377 | 70. 4 ( 8.8) | amyloidPET (SUVR >1.42) | 43.2 (24) | n.d. | MCI or AD dementia |
Strikwerda-Brown, 2022 [57] | Prevent AD, HABS (Harvard Aging Brain Study) | 281 | 72.1 (6.0) | amyloidPET (24 Centiloids for global Aβ) | n.d. | 32.7 (15.7 – 58.0) | MCI or unspecified dementia |
Villemagne, 2011 [51] | Austin Health Memory Disorders Clinic, USA | 106 | 73.1 (7.5) | amyloidPET (SUVR >1.5) | 20 | 20 | MCI |
Vos, 2013 [58] | Knight Alzheimer’s Disease Research Center (KADRC) of the Washington University School of Medicine (WUSM)in St. Louis, USA | 297 | 72.9 (6.0) | CSF Aβ42 (<459 pg/mL) | n.d. | 38.4 (12 - 156) | MCI or unspecified dementia |